Background. Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after transplantation.
ciency, particularly in patients with graft-versus-host disease (GVHD) [3] [4] [5] [6] .
Antibody response rates to the 23-valent pneumococcal polysaccharide vaccine (PPV23) after SCT are low; they are estimated to be 25% among patients with chronic GVHD or who receive steroid therapy and 50%-60% among other patients [5, 7, 8] . Neither repeated vaccination nor donor immunization [6, 9] improved this response. Although PPV23 vaccination is widely recommended [10, 11] , a more effective method of protecting against pneumococcal disease is needed for SCT recipients.
It is hypothesized that covalent conjugation of a polysaccharide to a protein carrier converts most of the immune response from T cell independent to T cell dependent, resulting in a stronger and longer-lasting antibody response [12] [13] [14] . The 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar; Wyeth Pharmaceuticals) is a solution of 7 capsular S. pneumoniae antigens, each conjugated to the diphtheria CRM197 protein.
An antibody titer у0.15 mg/mL for all 7 serotypes was found in 90% of infants given PCV7 at 2, 4, and 6 months of age [15] . Two studies involving allogeneic SCT recipients showed titers у0.5 mg/mL for all 7 serotypes in ∼70% of patients after 3 doses of vaccine [16, 17] . Severe invasive pneumococcal infection can occur early after allogeneic SCT [2] . However, responses to vaccines may be weak immediately after SCT [8, 18] , and the optimal timing of vaccination is yet not defined.
The aim of our study was to compare early vaccination, started at the beginning of the high-risk period (on day 100), with late vaccination, started 9 months after transplantation (control condition). Our hypothesis was that early vaccination was not inferior to late vaccination with respect to the rate of response (antibody titers, у0.15 mg/mL to all 7 PCV7 serotypes) at 1 month after the third PCV7 dose.
MATERIALS AND METHODS

Study design.
This was a randomized noninferiority trial conducted by the European Group for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party at 13 centers in 7 countries, from December 2001 through December 2004 (figures 1 and 2). The study was approved by the review boards of all participating institutions. Informed consent was obtained from the patients and/or their parents.
The primary end point was the percentage of patients with antibody titers у0.15 mg/mL to all 7 PCV7 serotypes at 1 month after the third dose of PCV7 (which was designated "S3" for serum sample 3). This primary end point was compared between 2 groups of patients randomly allocated to receive early vaccination (date of first dose, 100 days ‫ע‬ 10 days after transplantation) or late vaccination (date of first dose, 9 months ‫ע‬ 10 days after transplantation). The secondary end points included the geometric mean concentrations of specific antibodies to the 7 PCV7 serotypes before vaccination (at baseline, designated S1), 1 month after 3 doses of PCV7 (S3), immediately before PPV23 vaccination (S4), 1 month after PPV23 injection (S5), and 24 months after transplantation (S6). Because 2 studies of PCV7 in SCT recipients, published while our study was ongoing [16, 17] , used 0.5 mg/mL as the cutoff for defining an immune response, we conducted post hoc analyses using this 0.5-mg/mL cutoff.
All patients were followed up for 24 months after transplantation or until death, whichever occurred first. S. pneumoniae infections were recorded throughout the 21-month follow-up period. Supportive care, including prophylactic antibiotic treatment, was given at the discretion of the investigators.
Eligibility. Inclusion criteria were age 5-65 years; first allogeneic SCT; transplant from an HLA-identical sibling, a familial 1-antigen mismatched donor, or a matched unrelated donor; and myeloablative conditioning. Patients were included in the study at 85-109 days after transplantation.
Exclusion criteria were reduced-intensity conditioning, transplant from a haplo-identical donor, an intention to give donor lymphocyte infusions in a planned protocol, platelet count !50,000 platelets/mL, relapse of the underlying disease, uncontrolled grade IV acute GVHD, known allergy to PCV7, pneumococcal infection or vaccine since transplantation, immune globulin received within the past 4 weeks, life expectancy !2 weeks, and participation in another trial within the past 30 days.
Randomization. Randomization was performed by the EBMT London office. On the basis of EBMT registry megafile data, we estimated that ∼35% of patients would die between 3 months (date of eligibility) and 9 months (date of the first vaccine in the late vaccination group) after transplantation. The randomization procedure was designed to ensure that the number of vaccinated patients in the 2 groups would be similar despite this expected mortality rate. Randomization was performed by use of the minimization method, stratified by center, donor relatedness (i.e., related vs. unrelated), and source of cells (bone marrow or cord blood vs. peripheral stem cells).
Vaccine administration. PCV7 (0.5 mL) was injected intramuscularly 3 times at intervals of 1 month. A dose of PPV23 was given at 12 months after transplantation in the early vaccination group and at 18 months after transplantation in the late vaccination group (figure 2).
Definitions. Invasive pneumococcal disease was defined as isolation of S. pneumoniae in blood or CSF samples, irrespective of clinical symptoms, or in a bronchoscopy specimen from patients with pneumonia. GVHD was defined according to standard criteria [19] .
Serum sample collection and antibody measurements. The serum samples were labeled using code numbers, were immediately frozen at Ϫ20ЊC, and were shipped frozen by BioInova to the US Wyeth laboratories. Serum IgG responses to the 7 vaccine serotypes were determined using a doubleabsorbent serotype-specific antipneumococcal capsular polysaccharide ELISA, as described elsewhere [20] , and were expressed in units of mg/mL with use of the standard reference serum 89-SF. The quantification limit was 0.01 mg/mL for all serotypes. All serum samples were bar-coded and tested blindly by qualified laboratory personnel.
Statistical analyses. The primary end point was designed to see whether the immune response to early vaccination was noninferior to the immune response to late vaccination in terms of the percentage of patients with antibody titers у0.15 mg/mL to all the 7 PCV7 serotypes at 1 month after the third dose of vaccine. A 1-sided test was considered acceptable because this was a noninferiority trial. The noninferiority margin was set at 20% fewer patients with response, given the probable benefits associated with earlier protection.
The response rate to pneumococcal vaccines has been defined in various ways, reflecting the lack of data about the antibody titers that confer protection. However, the lowest published response rate for PPV23 was 25% in patients with chronic GVHD [5, 8, 13] . To define the response rate in our study, we chose 0.15 mg/mL as the cutoff for all 7 antibody titers, in accordance with the largest study performed involving infants [15, 21] . In a comparison of polysaccharide and conjugate Haemophilus influenzae vaccines, the conjugate vaccine produced a 30% higher response rate [12] . Therefore, a 55% ( ) response rate might be expected for PCV7 in 25% + 30% patients with GVHD. Given that GVHD was not expected in all patients, we estimated that 65% was a likely response rate.
The primary end point was tested using the 90% CI for dif- ference in response rate. If the lower 90% confidence limit was within the noninferiority region, we considered noninferiority to be established [22] . With , 142 patients (71 per a p 0.05 group) were required to obtain 80% power ( ) for esb p 0.20 tablishing noninferiority. Taking into account that 35% of patients in the late vaccination group were expected to drop out of the study before the first vaccine, we decided to include 181 patients in the study to expect 142 vaccinated patients.
For secondary end points, we used the x 2 test to compare the percentages of patients with titers у0.15 mg/mL between the 2 groups and used the nonparametric Mann-Whitney ranksum test to compare geometric mean concentrations. All P values were 2-sided with type I error fixed at 0.05. Because we wanted to allow comparisons between our results and those of the 2 studies published while our study was under way [16, 17] , we defined a response as titers у0.5 mg/mL to all 7 antigens for a post hoc analysis that repeated the primary end point and for a correlation analysis between patient and donor characteristics and the response rate. Factors yielding P values !.10 by univariate analysis were entered into a multivariable logistic regression model. A stepwise backward procedure was used with a cutoff significance level of .05 for deletion of factors from the model. Statistical tests were done using SPSS, version 14.0 (SPSS).
Safety. All patients given at least 1 dose of PCV7 were included in the safety analysis. Local side effects were recorded by the patient or their parents on diary cards for 7 days after each dose. Adverse events were reported according to European regulations, until 24 months after transplantation.
Role of funding sources. The study was funded by the EBMT (for data management and statistical analysis) and by Wyeth Pharmaceuticals (for provision and delivery of the vaccines, serum sample collection, and antibody assays). The EBMT sponsored the trial, organized data collection, owns the study data, and decided to publish this article.
RESULTS
Patient characteristics. From December 2001 through
December 2004, 158 patients were randomized to receive early vaccination (75 patients) or late vaccination (83 patients). The groups were well balanced (table 1). The overall Kaplan-Meier survival curves, starting at randomization, look similar for both groups, but the curves cross; therefore, any comparison by a log-rank test would be irrelevant. In the late vaccination group, 17 patients did not receive the study vaccine because of events that occurred between inclusion in the study and month 9 (figure 1).
Adherence to the protocol and study withdrawals. Five patients (1 in the early vaccination group and 4 in the late vaccination group) were lost to follow-up. In the early vaccination group, 3 patients decided to leave the study before the third dose of PCV7. At 24 months after transplantation, 44 of 75 patients in the early vaccination group and 42 of 83 patients in the late vaccination group were alive. The main reasons for failure to complete the study were leukemia relapse, death, and other serious adverse events, none of which was attributed by the safety committee to the study vaccine. Primary end point: response rate. One month after the third PCV7 dose, the response rate was not lower in the early vaccination group (45 [79%] of 57 patients) than in the late vaccination group (47 [82%] of 57 patients); the difference was Ϫ3.5% (90% CI, Ϫ15.6 to 8.6), which was well above the Ϫ20% noninferiority margin (table 2 and figure 3) .
Secondary end points. Before vaccination, the percentage of patients with antibody titers у0.15 mg/mL was significantly higher in the early vaccination group than in the late vaccination group (tables 2 and 3). Geometric mean concentrations at 1 month after the third PCV7 dose were not significantly different between the early and late vaccination groups for any of the serotypes. At 24 months after SCT, geometric mean concentrations and response rates were both significantly lower in the early vaccination group than in the late vaccination group for all serotypes except for 2: pn9v, for which only a trend was observed ( ), and pn23f. P p .06 Before vaccination, the percentage of patients with antibody titers у0.5 mg/mL was low in both groups (8% of patients in the early vaccination group and 2% of patients in the late vaccination group). The percentage of patients with antibody titers у0.5 mg/mL to all 7 vaccine antigens at 1 month after the third dose of PCV7 (figure 3) was not lower in the early vaccination group than in the late vaccination group: the difference was 1.7% (90% CI, Ϫ13.5 to 17), once again above the Ϫ20% margin. At study completion, there was a trend toward a higher response rate (with 0.5-mg/mL cutoff) in the late vaccination group.
Effect of the PPV23 vaccine. Variables correlated with antibody titers у0.5 mg/mL at 1 month after the third PCV7 dose. Because the response rate was not different between the 2 groups, correlations were studied in the overall population (table 4). In the univariate analysis, titers у0.5 mg/mL correlated significantly with donor age, absence of acute and chronic GVHD, and serum gammaglobulin level у4 g/L. By multivariate analysis, only chronic GVHD ( ) and donor age ( ) significantly impaired the P p .009 P p .03 response.
S. pneumoniae infections during the study. Three cases of invasive pneumococcal disease occurred in 2 patients. A patient in the early vaccination group who experienced bacteremia due to an unidentified serotype at 1 month after PPV23 injection survived without complications. A patient in the late vaccination group had 2 episodes of bacteremia with pneumonia caused by different serotypes (serotype 14, included in PCV7, and serotype 15, not included in PCV7 but included in PPV23) at 66 and 154 days after randomization (i.e., before vaccination), respectively. The patient survived the infections but died 13 days later from leukemia relapse. No patient died of pneumococcal infection.
Safety. Of the 123 reported adverse events, 80 consisted of injection-site pain and/or skin changes, and 8 were fever within 48 h after vaccination. Most of the 83 serious adverse events were disease relapses or transplant-related events (i.e, GVHD [10 patients] and relapse [25 patients]) . Seven fatal events occurred in the early vaccination group and 17 in the late vaccination group. The safety committee found no evidence that any of the serious adverse events were due to vaccination.
DISCUSSION
We investigated whether earlier vaccination of allogeneic SCT recipients with PCV7 was not inferior to later vaccination with regard to achieving protective antibody titers. Although pneumococcal infection is often viewed as a late complication of SCT, cases may occur within the first 6 months after transplantation [2] , at a time when the patient cannot respond to PPV23. In the EBMT study [2] , 7 of 51 episodes of pneumococcal infection occurred before day 100 after SCT, and 4 of 10 deaths occurred before 6 months after SCT. We found that the response rate to PCV7 after early vaccination that was started at 3 months after transplantation was not inferior to the response rate after vaccination that was started at 9 months after transplantation. Therefore, earlier vaccination should be recommended, to ensure protection against early life-threatening pneumococcal disease.
Three smaller studies of PCV7 in allogeneic SCT recipients have been published [16, 17, 23] . Molrine et al. [16] randomized 96 patients, mostly adults, and their donors to receive PCV7 or not to receive PCV7 before transplantation. All patients received PCV7 injections at 3, 6, and 12 months after transplantation. In the 65 assessable patients, donor immunization improved the rate of response (defined as antibody titers у0.5 mg/mL) after the first PCV7 dose (67% vs. 36%) but not after the third dose (75% vs. 64%). Furthermore, donor immunization is not always feasible for unrelated donors. Meisel et al. [17] immunized 53 children with 3 monthly doses of PCV7 started 6-9 months after transplantation. A response NOTE. Data are percentage of patients with response (no. with response/total no. of patients), unless otherwise indicated. S1, baseline (i.e., before vaccination); S3, 1 month after the third dose of PCV7; S6, 24 months after transplantation.
a By x 2 test. See figure 3 for equivalence test. Figure 3 . Difference in the response rate between the 2 groups (i.e., rate in the early vaccination group minus rate in the late vaccination group), with 2 different titer cutoffs to define response. PCV7, 7-valent pneumococcal conjugate vaccine.
(antibody titers у0.5 mg/mL) was noted in 74% of patients. Kumar et al. [23] compared PPV23 with PCV7 given to donors before transplantation and to transplant recipients at 6 months after transplantation. Rates of response (antibody titers у0.35 mg/mL and 2-fold increase from baseline) at 12 months among 44 patients were low in both groups but were better with PCV7 vaccination.
Comparisons of studies are hindered by differences in the definition of a response. We chose the classic cutoff of у0.15 mg/mL [15, 21] to assess our primary end point. After we started our study, Molrine et al. [16] and Meisel et al. [17] chose titers of у0.5 mg/mL to define response in SCT recipients; however, clinical evidence to substantiate the use of this threshold is lacking [15] . On the basis of a pooled analysis of healthy infants, the World Health Organization suggested in 2003 that titers у0.35 mg/mL may be protective [24] . However, no protective cutoff has been determined for adults. We conducted a post hoc analysis using 0.5 mg/mL as the cutoff for defining the response. Whatever the cutoff-0.15 or 0.5 mg/mL-response rates in our study were consistent with noninferiority of early vaccination.
Our study also provides the first data, to our knowledge, on the effects of PPV23 after PCV7 vaccination in SCT recipients.
Among patients who did not have a response after 3 doses of PCV7, 41% had a response to the PCV7 antigens after receiving a dose of PPV23. Thus, PPV23 not only may confer protection to 16 additional serotypes but also may boost the response to the PCV7 serotypes. This boost effect seems to be lower after early vaccination than after late vaccination. Administration of polysaccharide vaccine after conjugate vaccine is also supported by data showing that a prior exposure to polysaccharide impairs the response to subsequent conjugate antigen exposure [12, 25] .
Importantly, patients in the early vaccination group had higher prevaccination antibodies, compared with patients in the late vaccination group. This difference is probably ascribable to decreasing antibody production after transplantation.
Chronic GVHD and donor age were the only significant predictors of the immune response. Children usually exhibit excellent responses to conjugate vaccines, so the favorable effect of younger donor age is not surprising. Chronic GVHD impairs immune reconstitution and requires immunosuppressive therapy, 2 factors that explain its negative correlation with an antibody response. The fact that GVHD had no effect in earlier studies may be ascribable to smaller patient series [16, 17] and to pediatric cohorts [17] with a low risk of GVHD. NOTE. Response was defined as antibody titers у0.5 mg/mL to all 7 serotypes in PCV7. The primary end point was 1 month after the third dose of PCV7. GVHD, graft-versus-host disease.
a Only 1 patient in the early vaccination group received a transplant of cord blood; this patient was analyzed in the bone marrow transplant group.
Our study has several limitations. First, antibody titers to 6 of the 7 PCV7 serotypes decreased faster in the early vaccination group than in the late vaccination group. Although this finding does not argue against the benefit of early vaccination, it suggests a need for a PCV7 or PPV23 boost during the second year. Indeed, we compared 2 different timings of vaccination, and the times from PPV23 vaccination to study completion were different (12 vs. 6 months). Second, the benefits of PCV7 may vary across regions [26, 27] and according to the vaccine policy in the community [28] [29] [30] . Third, we did not use the 0.35-mg/mL cutoff proposed by the World Health Organization [24] for infants because we had, at that time, already defined our primary end point. We are aware that the minimum antibody titer associated with long-term clinical protection may be within the 0.15-0.5 mg/mL range in healthy infants [21] , but it is unknown whether this applies to immunocompromised adults.
On the basis of our results, we recommend early adminis-tration of 3 doses of PCV7 at monthly intervals, starting 3 months after transplantation, followed by PPV23. Whether a booster injection during the second posttransplantation year prevents the antibody decrease seen after early vaccination at 24 months cannot be determined from our study but should be a logical conclusion until further data are obtained.
